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Word count: 246 / 250 words  
Background: Clostridioides difficile infection (CDI) is associated with high healthcare 
demands and related costs.  
Aim: To evaluate the healthcare and economic burden of CDI in hospitalised patients with 
community- (HOCA-CDI) or hospital-associated CDI (HOHA-CDI) in the National Health 
Service in Scotland. 
Methods: A retrospective cohort study was conducted, examining data between August 
2010 and July 2013 from four patient-level Scottish datasets, linked to death data. Data 
examined included prior antimicrobial prescriptions in the community, hospitalisations, length 
of stay and mortality. Each CDI case was matched to three hospital-based controls on the 
basis of age, gender, hospital and date of admission. Descriptive economic evaluations were 
based on bed-day costs for different types of wards. 
Findings: Overall, 3304 CDI cases were included in the study. CDI was associated with 
additional median lengths of stay of 7.2 days for HOCA-CDI and 12.0 days for HOHA-CDI 
compared with their respective, matched controls. The 30-day mortality rate was 6.8% for 
HOCA-CDI and 12.4% for HOHA-CDI. Overall, recurrence within 90 days of the first CDI 
episode occurred in 373/2740 (13.6%) survivors. The median additional expenditure for each 
initial CDI case compared with matched controls was £1713. In the 6 months after the index 
hospitalisation, the cost associated with a CDI case was £5126 higher than for controls. 
Conclusion: Using routinely collected national data, we demonstrate the substantial burden 
of CDI on healthcare services, including lengthy hospital stays and readmissions, which 
increase the costs of managing patients with CDI compared with matched controls.  
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Clostridioides difficile infection (CDI) is the most common cause of healthcare-associated 
diarrhoea in developed countries and a major public health problem [1]. It is associated with 
high healthcare demands and related costs, with recurrence of infection and the need for 
readmission to hospital contributing to the burden of CDI [2]. Moreover, a recent study 
estimated an excess 30-day all-cause mortality of 10.9% in patients with CDI compared with 
matched patients without CDI [3]. While CDI is mainly a hospital-associated infection, a 
substantial proportion of cases have onset in or association with the community setting [4]. It 
is, therefore, important to explore both hospital- and community-associated CDI to obtain a 
comprehensive account of its impact on healthcare burden.  
In a study from Germany, the direct treatment cost of CDI was €18,463, compared with 
€14,531 for controls, with CDI prolonging the mean overall length of stay (LOS) by 8 days 
[5]. A study from Scotland found that LOS was extended by ≥15.8% in patients aged ≥65 
years with CDI compared with younger patients aged 15–64 years with CDI [6]. Furthermore, 
recurrence of CDI appears to prolong the LOS compared with an initial CDI episode, with 
some estimating a doubling of LOS [7]. Consequently, recurrent CDI substantially increases 
healthcare costs [7,8]. Dubberke et al. estimated the attributable inpatient cost of recurrent 
CDI to be US$11,631 over the 6-month period after the initial CDI episode [9].  
Owing to the considerable economic and healthcare burden of CDI, including recurrence, an 
accurate assessment of associated healthcare demands could help in the planning and 




Study design and data collection 
This was a cohort study, which examined linked data from four patient-level Scottish 
datasets. Scotland has mandatory reporting of CDI cases to Health Protection Scotland, with 
data held on the Electronic Communication of Surveillance in Scotland (ECOSS) system. 
Healthcare encounters also have mandatory recording of a unique patient identifier 
[Community Health Index (CHI) number], enabling patient-level linkage of data. Each CDI 
case from the diagnostic laboratories in Scotland were linked to community-based 
antimicrobial prescriptions and hospital admissions data. Prescriptions for antimicrobials 
dispensed in primary care were obtained from the Prescribing Information System (PIS). The 
PIS captures 96% of CHIs for all prescriptions dispensed in the community in Scotland [10].  
Hospital admissions data were obtained from the general/acute and inpatient day case 
Scottish Morbidity Record (SMR01) dataset [11]. Mortality data were obtained from National 
Records of Scotland and were linked to SMR01. 
Using ECOSS data, all CDI cases aged ≥15 years diagnosed during a hospital stay were 
identified covering the period between 1 August 2010 and 31 July 2013. Each hospital-onset 
CDI case was matched to up to three hospital-based controls, who were hospitalised at the 
same time as the case, on the basis of age (±5 years), gender, hospital and date of 
admission (±7 days). The index date for comparisons of outcomes for the controls was taken 
to be the date of diagnosis for the matched case.  
All data analysed were de-identified before being made available to researchers for analysis 
in the National Safe Haven, a secure repository for storing and sharing data for health 
research. Ethics permission for this study was not required as it used only non-identifiable 
routine data. Approval for the study was granted by the National Health Service (NHS) 




A CDI case was defined as a hospitalised patient who tested positive for C. difficile toxin in 
stool concurrent with diarrhoea not attributable to any other cause, or a patient with C. 
difficile culture-positive stool concurrent with pseudomembranous colitis diagnosis. Cases 
were defined as hospital onset community-associated (HOCA-CDI) if the diagnostic sample 
was taken 0–2 days after admission. CDI diagnosed from samples taken from day 3 of 
admission was defined as hospital onset hospital-associated (HOHA-CDI). If a patient was 
diagnosed twice with CDI within a 28-day period, the second positive test was considered 
part of the same infection episode. CDI recurrence was defined as a second CDI diagnosis 
≥28 days after the initial positive CDI test. Presumed cure of CDI occurred for patients who 
had a period of ≥28 days after the first positive C. difficile test with no positive result and no 
death. Any result reported in the ECOSS system as equivocal (i.e. positive for glutamate 
dehydrogenase but negative for C. difficile toxin) was removed from the final dataset. 
The exact date of CDI symptom onset is not systematically reported. A proxy for the onset 
date of CDI from the ECOSS system was the date that specimens were collected from 
patients or, when this was unavailable, the date that specimens were received by the testing 
laboratory or the date that results were reported.  
Assessments and statistical analyses 
LOS, additional LOS owing to CDI, mortality rates for ≤2 months post-CDI diagnosis and the 
recorded cause of death were assessed in cases and matched controls. If cases had 
multiple CDI episodes, one episode was randomly selected for analysis of LOS, readmission 
and survival. Additional LOS for both cases and controls was analysed using a multivariable 
parametric survival regression model with a log-normal distribution assumed for time to 
event. A robust sandwich covariance matrix estimator was used to account for the matched 
design. Additional LOS due to CDI was calculated by comparing the median outcomes 
predicted by the survival regression model, adjusting for deprivation, comorbidities and time 
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in hospital before CDI, for the cases and controls. The 95% confidence intervals (CIs) for the 
additional LOS was obtained by parametric bootstrapping 500 times. Patients who were 
transferred to another hospital environment, ending the continuous inpatient stay, were 
censored at the date of transfer. 
Analyses of CDI recurrence and its determinants included cases who survived the first CDI 
episode (i.e., did not die or were not censored within 28 days after the initial CDI diagnosis). 
Analysis of secondary CDI recurrence included all cases who survived at least two CDI 
recurrences. Multivariable competing risks models [12,13] were used to account for mortality 
when investigating recurrence. A sensitivity analysis was conducted in relation to CDI 
recurrence, replacing 28 days with 6 and 8 weeks as the presumed date of cure.  
A multivariable Cox proportional hazards survival model was applied to investigate the 
determinants of hospital readmission. The analysis was stratified by whether the first 
discharge was pre- or post-30 days after CDI diagnosis. Readmission rates within 6 months 
after CDI diagnosis and factors that may predict readmission were assessed in cases who 
were discharged from hospital before censor/date of death.  
A multivariable Cox proportional hazards survival model was used to compare survival 
between cases and matched controls. Matched cases and controls were included as strata 
in the model providing a different baseline hazard for each stratum to account for the 
matched design. 
In the analysis of potential risk factors, the following were recorded: comorbidities for the 
index admission; comorbidities reported in hospital admissions in the previous 5 years; 
number of hospital admissions in the previous year; number of antimicrobial prescriptions in 
primary care, total number of prescriptions (all drugs) and number of different prescriptions 
(based on approved name) dispensed in primary care in the previous year; Charlson 
comorbidity index [14–16] based on ICD-10 discharge codes from all hospital admissions in 
the 5 years prior to the CDI episode; care home residency (yes/no); and Scottish Index of 
Multiple Deprivation (SIMD) quintile [17]. 
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Cost analysis included LOS for both cases and matched controls. The first CDI episode was 
selected for the cost analysis if cases had multiple episodes. Costs were based on daily 
costs for different types of beds, such as beds on a general or critical care ward; see 
Supplementary Table AI. Descriptive economic evaluations were conducted for the NHS 
cost of managing the index CDI episode, the additional cost of managing the index CDI 
episode compared with matched controls, and NHS costs for hospital stay in the 6 months 
following the index CDI/matched control episodes. 
All statistical analyses were stratified by HOHA-CDI and HOCA-CDI. Analyses were 
performed using statistical software R (version 3.2.1) [18].   
Results 
Cases and matched controls 
There were 1297 HOCA-CDI cases and 3980 matched controls, and 2007 HOHA-CDI cases 
and 5536 matched controls. The identification and selection of cases and controls are shown 
in Figure 1. 
A greater number of previous hospital admissions and prescriptions for any medications 
were recorded in the cases, but other covariates were reasonably balanced between cases 
and controls (Table I and Supplementary Table AII).  
Outcomes 
Length of stay 
Adjusting for comorbidities on admission, previous admissions and social deprivation, the 
median LOS was more than double for CDI patients compared with controls and HOCA-CDI 
cases had an additional median LOS of 7.2 days (95% CI 4.7–12.0), while HOHA-CDI cases 
had an additional 12.0 days (95% CI 7.7–18.9) compared with their respective controls 




There were 1055 HOCA-CDI and 1685 HOHA-CDI cases eligible for analysis of recurrence 
(Figure 1). Overall, recurrence within 90 days of the first CDI episode occurred in 373/2740 
(13.6%) survivors (Figure 2). Recurrence rates over the 1-year period after the initial CDI 
diagnosis were similar for patients with HOCA-CDI and HOHA-CDI (Supplementary Table 
AIII). Recurrence occurred in 161/1055 (15.3%) HOCA-CDI cases and 212/1685 (12.6%) 
HOHA-CDI cases. The hazard ratio (HR, 95% CI) for recurrence relative to patients aged 
≤64 years was 1.51 (0.94–2.43) in patients aged 65–74 years, 1.98 (1.26–3.12) in patients 
aged 75–84 years and 2.16 (1.30–3.60) in patients aged ≥85 years.  
After the first recurrent CDI episode, 371 cases were presumed cured. Rates of a second 
CDI recurrence in the next 12 months were 48/196 (24.6%) for cases with initial HOCA-CDI 
and 61/175 (34.8%) for cases with initial HOHA-CDI.  
The sensitivity analyses revealed that the recurrence rates had little variation if replacing 28 
days post-infection with 6 and 8 weeks as the presumed date of cure (Supplementary 
Table AIII). 
Readmission to hospital 
There were 868 HOCA-CDI and 844 HOHA-CDI cases that had been discharged from 
hospital within 30 days of the initial CDI episode and were eligible for analysis of 
readmission. Readmission within 6 months of the CDI episode occurred in 526/868 (60.6%) 
HOCA-CDI cases and 489/844 (57.9%) HOHA-CDI cases. The reason for readmission did 
not differ substantially from the reason for index admission (Supplementary Table AIV). For 
patients discharged from hospital ≥30 days after the initial CDI episode, 71/129 (55.0%) 





Within 2 months of CDI diagnosis, 15.7% of cases with HOCA-CDI and 26.3% of cases with 
HOHA-CDI died in hospital, while the corresponding rates in control patients were 5.3% and 
11.6%, respectively (Table II).  
The in-hospital mortality rates and mortality rates within 2 months after CDI onset are shown 
in Figure 3. The 30-day mortality rate was 6.8% for HOCA-CDI cases and 12.4% for HOHA-
CDI cases. Adjusting for comorbidities on admission, previous hospital admissions and 
social deprivation score, compared with the corresponding controls, the HR for mortality was 
2.47 (95% CI 2.04–3.00) for HOCA-CDI cases and 2.01 (95% CI 1.79–2.25) for HOHA-CDI 
cases. 
Regardless of the origin of CDI, only comorbidities associated with the current admission 
were positively associated with mortality. There was no impact of social deprivation, 
antimicrobial or any medication prescriptions, or the number of hospital admissions in the 12 
months prior to admission. Admission from a care home was positively associated with 
mortality (HR 1.52, 95% CI 0.94–2.45 for HOCA-CDI and HR 1.57, 95% CI 1.19–2.08 for 
HOHA-CDI).  
Economic evaluation 
The median (lower quartile [LQ], upper quartile [UQ]) index inpatient cost was more than 
double for cases (£7456 [3728, 16,060]) compared to controls (£2796 [932, 8388]), (Figure 
4a). The median (LQ, UQ) additional cost associated with the index inpatient stay, calculated 
as the difference in median costs between cases in the index inpatient stay and matched 
controls, was £1713 (-1864, 8396; Figure 4b). Median (95% CI) longer-term costs based on 
all hospital stays in the 6 months after the index inpatient stay were £11,650 (5126, 23750) 




Using routinely collected national data, the present study identified and characterised the 
additional burden of CDI on the NHS in Scotland, not only in relation to patient outcome and 
hospital resource use, but also its impact on hospitalisation costs. Compared with matched 
controls, CDI is associated with additional median lengths of stay of 7.2 days for HOCA-CDI 
and 12.0 days for HOHA-CDI. The median additional expenditure for each CDI case is 
£1713. In the 6 months after the index hospitalisation, the cost associated with a CDI case is 
£5126 higher than for controls. As far as we are aware, this study offers the first European 
data on the economic burden of hospitalised cases of community-associated CDI [2]. It 
highlights the substantial healthcare and economic burden of CDI, including recurrent 
infection, and therefore provides a key rationale for campaigns that promote the early 
detection and treatment of cases and/or instigate infection control strategies to lessen the 
impact of CDI. Our findings could also help service providers to plan and prioritise resources. 
From our study, patients with CDI had longer lengths of stay and poorer outcomes than 
matched controls, and 1 in 7 patients had a second recurrence within 90 days of the initial 
infection. The LOS for patients with CDI is comparable to that in other studies based on 
European data [19], including a recently published study of CDI cases over a 6-year period 
in Scotland [6]. While our study did not compare the costs associated with index CDI and 
recurrent CDI episodes, we calculated the costs of admissions with recurrent CDI, 
contributing to the evidence that recurrent CDI adds substantially to the total cost of treating 
CDI.  
Our study also enabled a comparison of outcomes between community- and hospital-
associated CDI, when identified in the hospital. It has long been assumed that community-
associated CDI is less acute than hospital-associated CDI, but a substantial proportion of 
patients with community-associated CDI have serious sequelae, including severe infection, 
treatment failure, recurrent CDI and need for hospitalisation [20,21]. Although there is a 
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greater burden of hospital-associated disease, our study highlights that the mortality rate is 
similar in hospital- and community-associated CDI groups, when the latter is diagnosed in 
hospital. During the study period, ~801 community-associated, community-onset CDI cases 
were reported. The 30-day mortality rate of 12.4% for HOHA-CDI cases in our study was 
lower than the 17.5% reported for patients with hospital-associated CDI in a recent study 
from Scotland, although a greater proportion of patients in this other study had a higher 
Charlson comorbidity index compared with our study [6].  
While a recently published study also reported on the impact of CDI on LOS and mortality in 
patients in Scotland [6], no data on costs, recurrent infection or readmissions were included. 
The present study considers the current economic burden in the NHS in the United Kingdom 
and highlights the substantial cost associated with the acute management of CDI. We 
demonstrate that the burden of financial cost continues over an extended period of time, 
such that 6 months after the acute episode there is still a clear and significant difference in 
cost between cases and controls. Recent data from both 2016/17 and 2017/18 suggest that 
31% of all patients admitted to hospital have more than one admission within a year [22,23]; 
in our study, 57.7% of all hospital-onset CDI patients, from an earlier period (2010–2013), 
were readmitted within 6 months, suggesting that hospital-onset CDI is associated with 
particularly high rates of hospital readmission. 
A key strength of this study was the matched design for estimating costs. The study design 
also minimised the impact of bias and confounding factors on our analyses. As a limitation, 
we recognise that the quality of the retrospective data relies on the accuracy and 
completeness of the medical records, although it is presumed that cases and controls were 
subject to the same issues. Additionally, and unlike the definition provided by the European 
Centre for Disease Prevention and Control (ECDC), our definition of HOCA-CDI did not take 
into account previous hospital discharges ≤4 weeks of the current admission [24], and 
therefore some HOCA-CDI cases may have been healthcare-associated CDI. Likewise, our 
definition of recurrent CDI incorporated a different timeline (second CDI diagnosis ≥28 days 
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after the initial positive CDI test) than that from the ECDC (second CDI >2 weeks and <8 
weeks after onset of previous episode) [24]. Consequently, the current study may have 
under- or over-estimated HOCA-CDI and recurrent CDI. Also, the prescribing data used in 
our study were derived from primary care, rather than prescriptions received during the 
hospital stay. Furthermore, our analysis did not include cost data associated with prescribing 
or management within the community. Finally, by selecting the first CDI episode within the 
time period for individuals with multiple CDI episodes, we estimated the total additional costs 
of CDI within 6 months, which may have resulted in an overestimate compared with the 
selection of an episode at random, as had been done for the estimation of recurrence and 
readmission rates. 
In conclusion, CDI poses a substantial burden on healthcare services, including lengthy 
hospital stays, and after the infection, patients are at greater risk of readmission to hospital, 
even for non-CDI reasons. Consequently, there are increased costs associated with the 
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Table I. Demographics and characteristics of Clostridioides difficile infection cases and controls  







 Male  1385 (41.9) 3907 (41.1) 
 Female  1919 (58.0) 5609 (58.9) 
Age group, years   
 15–64 807 (24.4) 2263 (23.8) 
 65–74 730 (22.1) 2080 (21.9) 
 75–84 1049 (31.8) 3159 (33.2) 
 ≥85 718 (21.7) 2014 (21.2) 
Origin of CDI 
  
 HOCA  1297 (39.3) - 
 HOHA  2007 (60.7) - 
Admitted from a care home  
  
 No  3132 (94.8) 9125 (95.9) 
 Yes  172 (5.2) 391 (4.1) 
Charlson comorbidity index   
 0 1650 (49.9) 4676 (49.1) 
 1 524 (15.9) 1399 (14.7) 
22 
 
 2 600 (18.2) 1658 (17.4) 
 3 218 (6.6) 535 (5.6) 
 ≥4 180 (5.5) 385 (4.1) 
 Unknown 132 (4.0) 863 (9.1) 
Characteristic, median (IQR) 
  
Antimicrobial prescriptions in previous year  1 (0–3) 1 (0–3) 
Number of admissions in previous year  2 (1–3) 1 (0–3) 
Total prescriptions in previous year 58 (30–95) 48 (22–82) 
Different prescriptions in previous year 13 (8–18) 11 (6–16) 
Length of stay (days) before the date of CDI 5 (1–19) 4 (1–15) 






Table II. Additional length of stay, in-hospital mortality and discharge from hospital according 
to Clostridioides difficile infection type 










Median (95% CI) additional length 









Died in hospital, n (%) 204 (15.7) 211 (5.3) 527 (26.3) 644 (11.6) 
Discharged within 2 months, n 
(%) 
966 (74.5) 3535 (88.8) 1056 (52.6) 4007 (72.4) 
HOCA-CDI, hospital onset, community-associated Clostridioides difficile infection; HOHA-
CDI, hospital onset, hospital-associated Clostridioides difficile infection; CI, confidence 
interval 
aAdditional length of stay was adjusted according to comorbidities on admission, previous 






Figure 1. Identification and selection of Clostridioides difficile infection cases and controls 
Figure 2. Recurrence of Clostridioides difficile infection and readmission to hospital for any 
reason 
Figure 3. Mortality by origin of Clostridioides difficile infection  
Figure 4. Economic evaluation of Clostridioides difficile infection (CDI) cases and controls in 
relation to a) costs associated with first continuous inpatient stay after CDI diagnosis, b) 
additional costs of cases versus controls, and c) longer term costs in the 6 months after CDI 
diagnosis. For a), all costs valued above £40,000 were revalued as £40,000, while for b) and 





Figure 1. Identification and selection of Clostridioides difficile infection cases and controls 
 
CDI, Clostridioides difficile infection; HO, hospital onset; HOCA-CDI, hospital onset, 
community-associated CDI; HOHA-CDI, hospital onset hospital-associated CDI; SMR, 





Figure 2. Recurrence of Clostridioides difficile infection and readmission to hospital for any 
reason 
 




Figure 3. Mortality by origin of Clostridioides difficile infection   
 
CDI, Clostridioides difficile infection; HOCA-CDI, hospital onset, community-associated CDI; 


























Supplementary Table AI. Cost per day for each ward used in the calculation of costs in the 
analysis 
Ward type Proxy for: Cost per case 
(£) 
LOS Cost per day 
(£) 
Cardiac surgery Transplant unit 7,857 3.6 2,183 
Intensive care unit  9,105 4.2 2,168 
Burns unit  4,613 2.8 1,648 
A&E ward  961 0.6 1,602 
Medical paediatrics Children’s unit 1,418 1.1 1,289 
Cardiac care unit  1,893 1.9 996 
High dependency unit  2,265 2.5 906 
Spinal paralysis Spinal unit 27,072 49.8 544 




1,584 3.4 466 
Rehabilitation ward GORU 
Convalescent unit 
16,710 37.5 446 















Supplementary Table AII. Detailed demographics and characteristics of cases and controls 
  
HOCA-CDI HOHA-CDI 









N (%) N (%) N (%) N (%) 
Gender Female 805 (62.1) 2468 (62.0) 1114 (55.5) 3141 (56.7) 
Scottish Index of Multiple 
Deprivation 
1: most deprived 391 (30.1) 1104 (27.7) 571 (28.5) 1430 (25.8) 
 
2 318 (24.5) 917 (23.0) 463 (23.1) 1252 (22.6) 
 
3 250 (19.3) 739 (18.6) 374 (18.6) 1051 (19.0) 
 
4 182 (14.0) 623 (15.7) 306 (15.2) 951 (17.2) 
 
5: least deprived 152 (11.7) 583 (14.6) 284 (14.2) 830 (15.0) 
 
unknown 4 (0.3) 14 (0.4) 9 (0.4) 22 (0.4) 
Care home Yes 64 (4.9) 129 (3.2) 108 (5.4) 262 (4.7) 
Comorbidity - admission 1 Myocardial infarction 62 (4.8) 210 (5.3) 124 (6.2) 415 (7.5) 
 
2 Congestive heart failure, cardiomyopathy etc. 70 (5.4) 245 (6.2) 179 (8.9) 502 (9.1) 
 
3 Atherosclerosis, aortic aneurysm, vascular 
disease 
49 (3.8) 116 (2.9) 136 (6.8) 290 (5.2) 
 
4 Stroke etc. 34 (2.6) 185 (4.6) 178 (8.9) 498 (9) 
 
5 Dementia 54 (4.2) 192 (4.8) 139 (6.9) 458 (8.3) 
 
6 Bronchitis, pneumoconiosis etc. 173 (13.4) 510 (12.8) 262 (13.1) 812 (14.7) 
 
7 Gout, lupus, rheumatoid arthritis etc. 19 (1.5) 67 (1.7) 43 (2.1) 107 (1.9) 
 




9 Liver problems 60 (4.6) 67 (1.7) 92 (4.6) 132 (2.4) 
 
10 Diabetes 140 (10.8) 373 (9.4) 244 (12.2) 613 (11.1) 
 
11 Diabetes with complications 9 (0.7) 17 (0.4) 35 (1.7) 64 (1.2) 
 
12 Renal problems 148 (11.4) 233 (5.9) 281 (14) 536 (9.7) 
 
13 Cancer 220 (17) 600 (15.1) 359 (17.9) 853 (15.4) 
 
14 Alcohol-related liver failure, varices etc. 26 (2) 26 (0.7) 58 (2.9) 59 (1.1) 
 
15 Metastatic cancer 56 (4.3) 240 (6) 127 (6.3) 332 (6) 
Comorbidity - previous 5 years 1 Myocardial infarction 150 (11.6) 373 (9.4) 195 (9.7) 577 (10.4) 
 
2 Congestive heart failure, cardiomyopathy etc. 167 (12.9) 341 (8.6) 252 (12.6) 617 (11.1) 
 
3 Atherosclerosis, aortic aneurysm, vascular 
disease 
110 (8.5) 249 (6.3) 194 (9.7) 447 (8.1) 
 
4 Stroke etc. 131 (10.1) 324 (8.1) 255 (12.7) 617 (11.1) 
 
5 Dementia 52 (4) 148 (3.7) 105 (5.2) 322 (5.8) 
 
6 Bronchitis, pneumoconiosis etc. 286 (22.1) 739 (18.6) 357 (17.8) 1006 (18.2) 
 
7 Gout, lupus, rheumatoid arthritis etc. 63 (4.9) 146 (3.7) 75 (3.7) 184 (3.3) 
 
8 Gastro ulcers 74 (5.7) 106 (2.7) 73 (3.6) 121 (2.2) 
 
9 Liver problems 94 (7.3) 117 (2.9) 109 (5.4) 168 (3) 
 
10 Diabetes 206 (15.9) 519 (13) 346 (17.2) 775 (14) 
 
11 Diabetes with complications 33 (2.6) 68 (1.7) 86 (4.3) 137 (2.5) 
 
12 Renal problems 214 (16.6) 307 (7.7) 340 (16.9) 626 (11.3) 
 
13 Cancer 283 (21.9) 685 (17.2) 369 (18.4) 826 (14.9) 
 
14 Alcohol-related liver failure, varices etc. 53 (4.1) 55 (1.4) 58 (2.9) 99 (1.8) 
 















73 (61–81) 73 (61–82) 77 (67–85) 78 (68–85) 
Antimicrobial prescriptions in 
previous 12 months 
 
1 (0–4) 1 (0–3) 1 (0–3) 1 (0–3) 
Length of stay before the date of 
CDI 
 
1 (0–1) 1 (0–1) 14 (7–32) 12 (6–25) 
Number of admissions in previous 
12 months 
 
2 (1–4) 1 (0–3) 1 (0–3) 1 (0–2) 
Total prescriptions in previous  
12 months 
 
59 (29–97) 44 (19–78) 58 (31–92) 50 (25–84) 
Different prescriptions in previous  
12 months 
 
14 (8–19) 10 (6–16) 13 (8–18) 11 (7–17) 
Charlson comorbidity index - 
previous 5 years 
 
2 (0–4) 1 (0–2) 2 (0–3) 1 (0–3) 






Supplementary Table AIII. Recurrence rates (per 100-patient-years) of Clostridioides 
difficile infection (CDI) during the year after the date of cure, assuming the date of cure was 
4, 6 or 8 weeks after initial CDI diagnosis 
Time point HOCA-CDI (%) HOHA-CDI (%) 
Week 4 19.4 16.4 
Week 6 18.8 16.1 
Week 8 18.2 15.2 
CDI, Clostridioides difficile infection; HOCA-CDI, hospital onset, community-associated CDI; 





Supplementary Table AIV. Principal reason for initial hospitalisation and readmission to 






1 Myocardial infarction  5.6 5.2 
2 Congestive heart failure, cardiomyopathy etc.  7.5 6.4 
3 Atherosclerosis, aortic aneurysm, vascular disease  5.6 4.2 
4 Stroke etc.  6.4 3.1 
5 Dementia  5.8 3.7 
6 Bronchitis, pneumoconiosis etc.  13.2 11.0 
7 Gout, lupus, rheumatoid arthritis etc.  1.9 1.9 
8 Gastrointestinal or ulcers  2.2 1.1 
9 Liver problems  4.6 4.8 
10 Diabetes  11.6 12.2 
11 Diabetes with complications  1.3 1.9 
12 Hemiplegia, paraplegia etc.  0.2 0.6 
13 Renal problems  13.0 11.8 
14 Cancer  17.5 18.8 
15 Alcohol-related liver failure, varices etc.  2.5 2.0 
16 Metastatic cancer  5.5 4.0 
17 HIV related  0.2 0.6 
 
aPercentages of patients admitted for 17 principal reasons. Percentages do not add up to 
100 as some reasons are not included. Furthermore, the percentages associated with small 
numbers are subject to disclosure control so that exact numbers were not released when 
fewer than five patients were involved 
